Inducing cellular immune responses to human Papillomavirus...

Details Inducing cellular immune responses to human Papillomavirus... Inducing cellular immune responses to human Papillomavirus...

2006-04-11

2006-04-11

Housel, James (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C424S184100, C424S192100, C424S193100, C424S194100, C424S204100

Reexamination Certificate

active

07026443

ABSTRACT:
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

REFERENCES:
patent: 5180806 (1993-01-01), Dillner et al.
patent: 5200320 (1993-04-01), Sette et al.
patent: 5503829 (1996-04-01), Ladant et al.
patent: 5618536 (1997-04-01), Lowy et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5716620 (1998-02-01), Lowy et al.
patent: 5753233 (1998-05-01), Bleul et al.
patent: 5853755 (1998-12-01), Foldvari et al.
patent: 5855891 (1999-01-01), Lowy et al.
patent: 5871998 (1999-02-01), Lowy et al.
patent: 5985610 (1999-11-01), Lowy et al.
patent: 6034214 (2000-03-01), Boon et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 2002/0098197 (2002-07-01), Sette et al.
patent: 2002/0168374 (2002-11-01), Kubo et al.
patent: 2002/0177694 (2002-11-01), Sette et al.
patent: 0 044 710 (1982-01-01), None
patent: 0 226 513 (1987-06-01), None
patent: WO 91/18294 (1991-11-01), None
patent: WO 92/02543 (1992-02-01), None
patent: WO 92/12996 (1992-08-01), None
patent: WO 92/21033 (1992-11-01), None
patent: WO 93/03764 (1993-03-01), None
patent: WO 93/22338 (1993-11-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO 94/11738 (1994-05-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/31476 (1995-11-01), None
patent: WO 96/03140 (1996-02-01), None
patent: WO 96/19496 (1996-06-01), None
patent: WO 99/45954 (1999-09-01), None
NCBI Accession No.-X74479.
Azoury-Ziadeh et al., Viral Immunology 1999 vol. 12 pp. 297-312.
Murakami et al., Cancer Research , Mar. 15, 1999 pp. 1184-1187.
Castellanos, M.R., et al., “Synthetic Peptides Induce a Cytotoxic Response against Human Paillomavirus Type-18,”Gynecol. Oncol. 82:77-83, Academic Press (Jul. 2001).
Castellanos, M.R., et al., A rapid method to identify cytotoxic T-lymphocyte peptide epitopes from HLA-A2 (+) donors,Crit. Rev. Oncol. Hematol. 39:133-138, Elsevier Science Ireland, Ltd. (Jul./Aug. 2001).
“HPV and Animal PV Nucleic Acid Sequences,”Human Papillomaviruses 1997 Compendium, Part I. HPV and Animal PV Nucleotide Sequences in GenBank style, pp. I-1-I17, The Human Papillomavirus Database (Sep. 1997).
Kast, W.M., et al., “Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins,”J. Immunol. 152:3904-3912, The American Association of Immunologists (Apr. 1994).
Ressing, M.E., et al., “Human CTL Epitopes Encoded by Human Papillomavirus Type 15 E6 and E7 Identified Through In Vivo and In Vitro Immunogenecity Studies of HLA-A*0201-Binding Peptides,”J. Immunol. 154:5934-5942, The American Association of Immunologists (Jun. 1995).
Rowen, D., and Lacey, C., “Toward a human papillomavirus vaccine,”Dermatologic Clinics 16:835-838, W.B. Saunders (Oct. 1998).
Yoon, H., et al., “Synthetic peptides of human papillomavirus type 185 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors,”Virus Res. 54:23-29, Elsevier Science B.V. (Mar. 1998).
Copy of co-pending U.S. Appl. No. 08/205,713, filed Mar. 4, 1974, inventor Gray (Not Published).
Copy of co-pending U.S. Appl. No. 08/344,824, filed Nov. 23, 1994, inventors Sette et al., (Not Published).
Copy of co-pending U.S. Appl. No. 08/347,610, filed Dec. 1, 1994, inventors Kubo et al., (Not Published).
Copy of co-pending U.S. Appl. No. 09/017,524, filed Feb. 3, 1998, inventors Kubo et al., (Not Published).
Copy of co-pending U.S. Appl. No. 10/149,136, filed Jun. 10, 2002, inventors Sette et al., (Published).
Aichele, P., et al., “Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide,”J. Exp. Med. 171:1815-1820, Rockefeller University Press (1990).
Alexander, J., et al., “Derivation of HLA-A11/KbTransgenic Mice. Functional CTL Repertoire and Recognition of Human A11-Restricted CTL Epitopes,”J. Immunol. 159:4753-4761, The American Association of Immunologists (Nov. 1997).
Bergmann, C.C., et al., “Differential Effects of Flanking Residues on Presentation of Epitopes from Chimeric Peptides,”J. Virol. 68:5306-5310, American Society for Microbiology (Aug. 1994).
Bertoni, R., et al., “Human Histocompatibility Leukocyte Antigen-binding Supermotifs Predict Broadly Cross-reactive Cytotoxic T Lymphocyte Responses in Patients with Acute Hepatitis,”J. Clin. Invest. 100:503-513, The American Society for Clinical Investigation, Inc. (Aug. 1997).
Bertoni, R., et al., “Human Class I Supertypes and CTL Repertoires Extend to Chimpanzees,”J. Immunol. 161:4447-4455, American Association of Immunologists (Oct. 1998).
Bjorkman, P.J., et al., “Structure of the human class I histocompatibility antigen, HLA-A2,”Nature 329:506-512, Macmillan Publishers, Ltd. (1987).
Bjorkman, P.J., et al., “The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens,”Nature 329:512-518, Macmillan Publishers, Ltd. (1987).
Buus, S., et al., “Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia,”Science 242:1045-1047, American Association for the Advancement of Science (1988).
Carreno, B.M., et al., “HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides,”Proc. Natl. Acad. Sci. USA 87:3420-3424, National Academy Press (1990).
Corr, M., et al., “Endogenous Peptides of a Soluble Major Histocompatibility Complex Class I Molecule, H-2Lds: Sequence Motif, Quantitative Binding, and Molecular Modeling of the Complex,”J. Exp. Med. 176:1681-1692, Rockefeller University Press (Dec. 1992).
De Bruijn, M.L.H., et al., “Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses,”Eur. J. Immunol. 21:2963-2970, VCH Verlagsgesellschaft mbH (1991).
Del Val, M., et al., “Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on Its Neighboring Residues in the Protein,”Cell 66:1145-1153, Cell Press (1991).
Deres, K., et al., “In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopetide vaccine,”Nature 342:561-564, Macmillan Publishers, Ltd. (1989).
Dibrino, M., et al., “HLA-A1 and HLA-A3 T Cell Epitopes Derived from Influenza Virus Proteins Predicted from Peptide Binding Motifs,”J. Immunol. 151:5930-5935, The Association of Immunologists (Dec. 1993).
DiBrino, M., et al., “Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides,”Proc. Natl. Acad. Sci. USA 90:1508-1512, National Academy Press (Feb. 1993).
Ding, Y.-H., et al., “Two Human T Cell Receptors Bind in a Similar Diagonal Mode to the HLA-A2/Tax Peptide Complex Using Different TCR Amino Acids,”Immunity 8:403-11, Cell Press (Apr. 1998).
Eisenlohr, L.C., et al., “Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes,”J. Exp. Med. 175:481-487, The Rockefeller University Press (Feb. 1992).
Engelhard, V.H., “Structure of peptides associated with MHC Class I molecules,”Curr. Opin. Immunol. 6:13-23, Current Biology, Ltd. (Feb. 1994).
Falk, K., et al., “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,”Nature 351:290-296, Macmillan Publishers, Ltd. (1991).
Falk, K., et al., “MHC peptide motif register. Peptide motifs of HLA-B35 and -B37 molecules,”Immunogenetics 38:161-162, Springer-Verlag (Apr. 1993).
Falk, K., et al., “Allele-specific peptide ligand

Affiliated with

Also associated with

Rating

Inducing cellular immune responses to human Papillomavirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inducing cellular immune responses to human Papillomavirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inducing cellular immune responses to human Papillomavirus... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3609750